Research statistics
Amycretin research: publications and trials
At a glance
Publications, all years
16
Since 2025
Publications in 2026 so far
10
Through November 15, 2026
Human clinical research
31.3%
5 of 16 classified
Registered clinical trials
12
ClinicalTrials.gov
Randomized controlled trials
4
Publications reporting an RCT in people
Systematic reviews and meta-analyses
1
Preclinical studies
12.5%
1 animal · 0 in vitro · 1 computational
Records that only mention it
10
Not counted above
Status in the library: In clinical trials. Groups: Amylin analogues, GLP-1 receptor agonists.
What to keep in mind
- Fewer than 25 publications are indexed, so year-to-year changes are not meaningful.
Publications by year
Amycretin publications by year and evidence
Show the data
| Year | Human clinical research | Preclinical (animal, in vitro, computational) | Reviews and meta-analyses | Other and not yet classified | Total |
|---|---|---|---|---|---|
| 2025 | 2 | 2 | 1 | 1 | 6 |
| 2026 (to date) | 3 | 0 | 6 | 1 | 10 |
Study types
| Review | 6 |
|---|---|
| Randomized controlled trial | 4 |
| Editorial, letter or other | 2 |
| Animal study | 1 |
| Other clinical trial | 1 |
| Computational study | 1 |
| Systematic review | 1 |
Research areas
From MeSH major topics. A paper can be in several areas.
| Metabolic health | 12 |
|---|---|
| Obesity and weight management | 11 |
| Endocrinology | 6 |
| Reproductive and sexual health | 1 |
Registered clinical trials
A registration is not a result.
Not yet recruiting: 6 · Recruiting: 6
Phase 1: 3 · Phase 3: 9
Human trials and evidence reviews
Meta-analyses, systematic reviews and trials in people, newest first.
- Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review.
Annals of internal medicine · September 1, 2026 · Systematic review · cited 0 times
PMID 42673585 · DOI 10.7326/annals-25-05519 · Reviews and meta-analyses
- Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial.
Lancet (London, England) · July 30, 2026 · Randomized controlled trial · cited 2 times
PMID 42532080 · DOI 10.1016/s0140-6736(26)01248-1 · Human clinical research
- Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial.
Lancet (London, England) · July 30, 2026 · Randomized controlled trial · cited 2 times
PMID 42532079 · DOI 10.1016/s0140-6736(26)01247-x · Human clinical research
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial.
Lancet (London, England) · June 20, 2025 · Randomized controlled trial · cited 45 times
PMID 40550229 · DOI 10.1016/s0140-6736(25)01176-6 · Human clinical research
- Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study.
Lancet (London, England) · June 20, 2025 · Randomized controlled trial · cited 76 times
PMID 40550231 · DOI 10.1016/s0140-6736(25)01185-7 · Human clinical research
- Renal Impairment Does Not Affect Pharmacokinetics, Safety or Tolerability of Zenagamtide.
Diabetes, obesity & metabolism · July 13, 2026 · Other clinical trial · cited 0 times · open access
PMID 42443140 · DOI 10.1111/dom.71096 · Human clinical research
Most cited
By OpenAlex citation count. Citations measure attention, not quality or correctness.
- Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study.
Lancet (London, England) · June 20, 2025 · Randomized controlled trial · cited 76 times
PMID 40550231 · DOI 10.1016/s0140-6736(25)01185-7 · Human clinical research
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial.
Lancet (London, England) · June 20, 2025 · Randomized controlled trial · cited 45 times
PMID 40550229 · DOI 10.1016/s0140-6736(25)01176-6 · Human clinical research
- Novel GLP-1-based Medications for Type 2 Diabetes and Obesity.
Endocrine reviews · March 1, 2026 · Review · cited 37 times
PMID 41054801 · DOI 10.1210/endrev/bnaf036 · Reviews and meta-analyses
- The effect of amycretin, a unimolecular glucagon-like peptide-1 and amylin receptor agonist, on body weight and metabolic dysfunction in mice and rats.
EBioMedicine · July 23, 2025 · Animal study · cited 26 times · open access
PMID 40706446 · DOI 10.1016/j.ebiom.2025.105862 · Animal studies
- Amylin receptors as therapeutic targets in obesity: Emerging peptide-based strategies.
Vascular pharmacology · December 2, 2025 · Review · cited 7 times
PMID 41344603 · DOI 10.1016/j.vph.2025.107563 · Reviews and meta-analyses
Latest publications
- Unapproved GLP-1 Drugs Retatrutide and Zenagamtide Sold Online Are No Bargain.
JAMA · November 1, 2026 · Editorial, letter or other · cited 0 times
PMID 42853576 · DOI 10.1001/jama.2026.20514 · Commentary and other
- New Amylin-Based Agonists for the Treatment of Obesity and Type 2 Diabetes Mellitus.
Diabetes therapy : research, treatment and education of diabetes and related disorders · September 28, 2026 · Review · cited 0 times · open access
PMID 42803913 · DOI 10.1007/s13300-026-01921-0 · Reviews and meta-analyses
- Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review.
Annals of internal medicine · September 1, 2026 · Systematic review · cited 0 times
PMID 42673585 · DOI 10.7326/annals-25-05519 · Reviews and meta-analyses
- Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial.
Lancet (London, England) · July 30, 2026 · Randomized controlled trial · cited 2 times
PMID 42532080 · DOI 10.1016/s0140-6736(26)01248-1 · Human clinical research
- Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial.
Lancet (London, England) · July 30, 2026 · Randomized controlled trial · cited 2 times
PMID 42532079 · DOI 10.1016/s0140-6736(26)01247-x · Human clinical research
- Renal Impairment Does Not Affect Pharmacokinetics, Safety or Tolerability of Zenagamtide.
Diabetes, obesity & metabolism · July 13, 2026 · Other clinical trial · cited 0 times · open access
PMID 42443140 · DOI 10.1111/dom.71096 · Human clinical research
- Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis.
Endocrinology, diabetes & metabolism · May 1, 2026 · Review · cited 0 times · open access
PMID 42175595 · DOI 10.1002/edm2.70247 · Reviews and meta-analyses
- Amycretin in obesity: Mechanisms, clinical efficacy, and future perspectives.
Metabolism: clinical and experimental · March 17, 2026 · Review · cited 2 times
PMID 41850421 · DOI 10.1016/j.metabol.2026.156594 · Reviews and meta-analyses
- Novel GLP-1-based Medications for Type 2 Diabetes and Obesity.
Endocrine reviews · March 1, 2026 · Review · cited 37 times
PMID 41054801 · DOI 10.1210/endrev/bnaf036 · Reviews and meta-analyses
- Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes.
Peptides · February 24, 2026 · Review · cited 6 times · open access
PMID 41747885 · DOI 10.1016/j.peptides.2026.171480 · Reviews and meta-analyses
How this is counted
PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology
Search terms: Amycretin; NN9487; Zenagamtide
((TITLE_ABS:"Amycretin" OR CHEM:"Amycretin") OR (TITLE_ABS:"NN9487" OR CHEM:"NN9487" OR TITLE_ABS:"NN 9487" OR CHEM:"NN 9487") OR (TITLE_ABS:"Zenagamtide" OR CHEM:"Zenagamtide")) AND SRC:MED
Cite this page
Peptide Library. (2026, November 16). Amycretin research statistics (Version weekly-2026-11-15) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/amycretin